Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 6, 2011, Pages 713-725

  Møller, Jonas B ^a   Jusko, William J ^b   Gao, Wei ^b   Hansen, Torben ^c   Pedersen, Oluf ^c   Holst, Jens J ^d   Overgaard, Rune V ^a   Madsen, Henrik ^e   Ingwersen, Steen H ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY AT BUFFALO   (United States)

^c HAGEDORN RESEARCH INSTITUTE   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

GLP 1; Indirect response model; L cells; NONMEM; Oral glucose tolerance test (OGTT)

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; BLOOD ANALYSIS; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN SYNTHESIS; L CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POPULATION MODEL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENTEROENDOCRINE CELLS; FASTING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MIDDLE AGED; MODELS, STATISTICAL;

EID: 84855680173     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9216-2     Document Type: Review

References (25)

1. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88(1):220-224 (Pubitemid 36115169)
2. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM (2001) GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 281(2):E242-E247
3. Lim GE, Brubaker PL (2006) Glucagon-like peptide 1 secretion by the L-cell. Diabetes 55(Suppl 2): S70-S77
4. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53(3):654-662 (Pubitemid 38270634)
5. Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, Ahrén B (2004) Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 53(5):624-631 (Pubitemid 38596536)
6. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T (2007) Reduced incretin effect in type 2 diabetes. Diabetes 56(8):1951-1959
7. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Pharmacodyn 21(4):457-478 (Pubitemid 24025269)
8. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86(8):3717-3723 (Pubitemid 32755966)
9. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Vølund A, Borch-Johnsen K, Pedersen O (2007) The BIGTT test. Diabetes Care 30(2):257-262
10. American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 30(suppl 1):S5-S10
11. Andersen L, Dinesen B, Jorgensen P, Poulsen F, Roder M (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39(4):578-582 (Pubitemid 23118305)
12. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4):535-539 (Pubitemid 24096293)
13. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271(3):E458-E464
14. Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ (2004) Modeling the metabolic effects of terbutaline in [beta]2-adrenergic receptor diplotypes[ast]. Clin Pharmacol Ther 76(1): 27-37 (Pubitemid 38844731)
15. Woo S, Pawaskar D, Jusko W (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36(5):381-405
16. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409-1439 (Pubitemid 350041474)
17. Savic R, Jonker D, Kerbusch T, Karlsson M (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34(5):711-726 (Pubitemid 47477040)
18. Silber HE, Frey N, Karlsson MO (2010) An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol 50(3):246-256
19. Møller J, Overgaard R, Madsen H, Hansen T, Pedersen O, Ingwersen S (2010) Predictive performance for population models using stochastic differential equations applied on data from an oral glucose tolerance test. J Pharmacokinet Pharmacodyn 37(1):85-98
20. Savic R, Karlsson M (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: Problems and solutions. AAPS J 11(3):558-569
21. Rask E, Olsson T, Søderberg S, Johnson O, Seckl J, Holst JJ, Ahrén B (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24(9):1640-1645 (Pubitemid 33716463)
22. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C (2004) Minimal model estimation of glucose absorption and insulin sensitivity from oral test: Validation with a tracer method. Am J Physiol Endocrinol Metab 287(4):E637-E643 (Pubitemid 39237891)
23. Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A (2008) Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Comput Methods Prog Biomed 89(2):132-140
24. Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42(5):658-661 (Pubitemid 23127154)
25. Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 330(8571):1300-1304 (Pubitemid 17156636)